RxDoctor Payments Data

Hilary Thomas, MD

Endocrinology, Diabetes & Metabolism · Asheville, NCNPI 1639375801

Payments from drug & device makers

$9,934in general payments, 2019–2025

Across 142 payments — averaging $69.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tandem Diabetes Care, Inc.$7K
  • Medtronic$836
  • Amgen$319
  • Johnson & Johnson$205
  • Insulet Corporation$188
  • Lilly USA, LLC$180
  • plus $908 from 18 others

What the payments were for

  • Speaking & faculty fees$7,20072%
  • Travel & lodging$2923%
  • Food & beverage$2,41324%
  • Education$290%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,934 in reported general payments places this provider in the 70th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.

See all endocrinology, diabetes & metabolism providers in North Carolina

Medicare billing

Part B allowed, 2024
$143,133
Medicare patients
351
Services billed
5,393

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide205$373,799
JardianceEmpagliflozin158$182,661
MounjaroTirzepatide77$115,268
TrulicityDulaglutide62$70,874
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/736$58,334
Tresiba Flextouch U-100Insulin Degludec46$49,168
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog21$44,038
Novolog FlexpenInsulin Aspart77$34,184
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog22$23,709
InvokanaCanagliflozin18$21,164
Lantus SolostarInsulin Glargine,hum.Rec.Anlog164$21,104
Synjardy XrEmpagliflozin/Metformin Hcl11$19,727
SynthroidLevothyroxine Sodium192$19,620
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog32$17,198
Repatha SureclickEvolocumab18$16,963

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$60$381,506225 claims
Boehringer IngelheimJardiance, Synjardy Xr$143$202,388169 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro$180$199,547199 claims
Johnson & JohnsonInvokana$205$21,16418 claims
AbbVieSynthroid, Armour Thyroid$14$20,597218 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$18$16,20436 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.

Other endocrinology, diabetes & metabolism in Asheville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →